Authors
Francine Grodstein, JoAnn E Manson, Graham A Colditz, Walter C Willett, Frank E Speizer, Meir J Stampfer
Publication date
2000/12/19
Journal
Annals of internal medicine
Volume
133
Issue
12
Pages
933-941
Publisher
American College of Physicians
Description
Background
Most primary prevention studies have found that long-term users of postmenopausal hormone therapy are at lower risk for coronary events, but numerous questions remain. An adverse influence of hormone therapy on cardiovascular risk has been suggested during the initial year of use; however, few data are available on short-term hormone therapy. In addition, the cardiovascular effects of daily doses of oral conjugated estrogen lower than 0.625 mg are unknown, and few studies have examined estrogen plus progestin in this regard.
Objective
To investigate duration, dose, and type of postmenopausal hormone therapy and primary prevention of cardiovascular disease.
Design
Prospective, observational cohort study.
Setting
Nurses' Health Study, with follow-up from 1976 to 1996 …
Total citations
200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024451231201199999777886464946383935323832412727231215
Scholar articles
F Grodstein, JAE Manson, GA Colditz, WC Willett… - Annals of internal medicine, 2000
F Grodstein, JE Manson, GA Colditz - ACC Current Journal Review, 2001